research Nrf2 Activation Enhances the Healing of Cutaneous Wounds Through the Activation of Hair Follicle Stem Cells
Activating Nrf2 helps wounds heal faster by increasing hair follicle stem cells.
Search
for
Sort by
Research
570-600 / 1000+ results 
research Efficacy of Topical Tofacitinib in Promoting Hair Growth in Non-Scarring Alopecia
Topical tofacitinib is effective in promoting hair growth for non-scarring alopecia.
research Developing Optical Biometrics Using Optical Coherence Tomography for Medical Screening and Diagnosis
OCT can effectively screen and diagnose various medical conditions non-invasively.
research Disorders of the Scalp and Hair
Different scalp and hair disorders are more common in certain ethnic groups, with the most common being androgenetic alopecia, which is treated with medications like minoxidil and finasteride.
research Safety of Four Treatment Regimens in Early Rheumatoid Arthritis
All four treatments for early rheumatoid arthritis had similar safety profiles.
research Alopecia Areata: An Autoimmune Hair Loss Condition
Alopecia Areata is an unpredictable autoimmune hair loss condition with limited and variable treatment effectiveness.
research Treatment of Alopecia Areata in Mice by Stimulating Hair Follicles Using Parathyroid Hormone Agonists Linked to a Collagen Binding Domain
A protein combining parathyroid hormone and collagen helped hair regrow in mice with a hair loss condition.
research Methotrexate Dose Has Minimal Effects on Methotrexate-Related Toxicity in Patients with Early Rheumatoid Arthritis Treated in Combination with Adalimumab – Results of Concerto Trial
Methotrexate dose has little effect on its toxicity when used with adalimumab for early rheumatoid arthritis.
research British Society for Dermatopathology 2011 Findings
Dermatologists give better information on pathology forms, hypersensitivity vasculitis is a common skin issue, misdiagnoses can occur, and various skin conditions are linked to loss of elastin or genetic factors.
research Sulfotransferase SULT1A1 Activity in Hair Follicle: A Prognostic Marker of Response to Minoxidil Treatment in Androgenetic Alopecia
Sulfotransferase SULT1A1 activity may predict minoxidil treatment success for hair loss.
research Changes in Urine Androgen and Prostaglandin Levels During Finasteride Treatment
Finasteride treatment lowers urine androgen and prostaglandin levels, making them potential markers for effectiveness.
research Real-World Experience of Efficacy and Safety of Baricitinib in Korean Patients with Severe Alopecia Areata
Baricitinib 4 mg is effective and safe for treating severe alopecia areata.
research Switching Between Tofacitinib and Baricitinib in Alopecia Areata: A Review of Clinical Response
Switching between the medications tofacitinib and baricitinib can be effective for treating hair loss in alopecia areata.
research Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications
Baricitinib, a drug for rheumatoid arthritis, atopic dermatitis, and alopecia areata, is generally safe with low risk of major side effects, even in patients with risk factors. It's also effective in promoting hair regrowth in alopecia areata patients.
research Ritlecitinib And Brepocitinib Demonstrate Significant Improvement In Scalp Alopecia Areata Biomarkers
Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.
research Topical Tofacitinib for Patients with Lichen Planopilaris and/or Frontal Fibrosing Alopecia
Topical tofacitinib cream may help treat certain hair loss conditions with fewer risks.
research Clinical Response to Adjunctive Platelet-Rich Plasma Injections in a Patient with Alopecia Universalis on Oral Tofacitinib
A woman with severe hair loss saw significant hair regrowth after adding platelet-rich plasma injections to her treatment with tofacitinib.
research Treatment of Moderate-to-Severe Alopecia Areata in Adolescents With Baricitinib: A Retrospective Review of 29 Patients
Baricitinib helped most teenagers with severe hair loss regrow hair and had mild side effects.
research COVID-19 Vaccination Related Exacerbations of Hair Loss in Patients With Moderate-to-Severe Alopecia Areata on Systemic Therapy
COVID-19 vaccines may rarely worsen hair loss in people with severe alopecia, but the benefits of vaccination still outweigh this risk.
research Delayed Granulomatous Eruption of the Nose Associated with Ruxolitinib
Ruxolitinib can cause a delayed skin reaction on the nose.
research Selective Inhibition of JAK3 Signaling Is Sufficient to Reverse Alopecia Areata
Blocking JAK3 signaling can reverse hair loss from alopecia areata.
research JAK Inhibition in the Treatment of Alopecia Areata: A Promising New Dawn?
JAK inhibitors are a promising new treatment for hair loss and nail problems in alopecia areata.
research Maintenance, Withdrawal, and Re-Treatment with Ritlecitinib and Brepocitinib in Patients with Alopecia Areata in a Single-Blind Extension of a Phase 2a Randomized Clinical Trial
Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.
research Epigallocatechin-3 Gallate Inhibits STAT-1/JAK2/IRF-1/HLA-DR/HLA-B and Reduces CD8 NKG2D Lymphocytes in Alopecia Areata Patients
EGCG may help treat alopecia areata by blocking certain immune responses and reducing specific harmful immune cells.
research Incidence Rates of Infections, Malignancies, Thromboembolism, and Cardiovascular Events in an Alopecia Areata Cohort from a US Claims Database
People with Alopecia Areata have more herpes simplex infections but similar rates of cancer, blood clots, and heart disease compared to those without it.
research Spontaneous Complete Resolution of Alopecia Totalis Post SARS-CoV-2 Infection
A woman's complete hair loss condition improved after recovering from COVID-19.
research Characteristics and Outcomes of Patients on Tofacitinib for Alopecia Areata or Rheumatoid Arthritis: A Retrospective Cohort Study
Patients with rheumatoid arthritis using tofacitinib had more serious side effects than those with alopecia areata.
research Effectiveness of OR-101, a Next Generation Highly Selective JAK3 Inhibitor, in a Humanized Murine Model of Alopecia Areata
OR-101 shows promise for treating alopecia areata by improving hair growth.
research Comparison of Ruxolitinib and a Collagen-Targeted PTH-Based Hair Cycle Stimulant on Hair Follicle Counts and Hair Growth in the C3H/HeJ Engrafted Mouse Model of Alopecia Areata
A PTH-based treatment improved hair regrowth better than ruxolitinib in a mouse model of hair loss.
research A Case of Topical Ruxolitinib Treatment Failure in Alopecia Areata
Topical ruxolitinib failed to regrow hair in a 66-year-old with alopecia areata.